Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study

Christine M. Durand; Brittany Barnaba; Sile Yu; Diane M. Brown; Michael A. Chattergoon; Nichole Bair; Fizza F. Naqvi; Mark Sulkowski; Dorry L. Segev; Niraj M. Desai

doi:10.7326/M20-1468

Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study

Christine M. Durand, Brittany Barnaba, Sile Yu, Diane M. Brown, Michael A. Chattergoon, Nichole Bair, Fizza F. Naqvi, Mark Sulkowski, Dorry L. Segev, Niraj M. Desai

School of Medicine

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	137-138
Number of pages	2
Journal	Annals of internal medicine
Volume	174
Issue number	1
DOIs	https://doi.org/10.7326/M20-1468
State	Published - Jan 1 2021

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.7326/M20-1468

Cite this

Durand, C. M., Barnaba, B., Yu, S., Brown, D. M., Chattergoon, M. A., Bair, N., Naqvi, F. F., Sulkowski, M., Segev, D. L., & Desai, N. M. (2021). Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study. Annals of internal medicine, 174(1), 137-138. https://doi.org/10.7326/M20-1468

Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study. / Durand, Christine M.; Barnaba, Brittany; Yu, Sile et al.
In: Annals of internal medicine, Vol. 174, No. 1, 01.01.2021, p. 137-138.

Research output: Contribution to journal › Letter › peer-review

Durand, CM, Barnaba, B, Yu, S, Brown, DM, Chattergoon, MA, Bair, N, Naqvi, FF , Sulkowski, M, Segev, DL & Desai, NM 2021, 'Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study', Annals of internal medicine, vol. 174, no. 1, pp. 137-138. https://doi.org/10.7326/M20-1468

@article{619392f8f3c348c382809d1611f79c78,

title = "Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study",

author = "Durand, {Christine M.} and Brittany Barnaba and Sile Yu and Brown, {Diane M.} and Chattergoon, {Michael A.} and Nichole Bair and Naqvi, {Fizza F.} and Mark Sulkowski and Segev, {Dorry L.} and Desai, {Niraj M.}",

note = "Funding Information: Financial Support: Dr. Durand is supported by National Cancer Institute grant K23CA177321-01A1. Dr. Segev is supported by grant K24DK101828 from the National Institute of Diabetes and Digestive and Kidney Diseases. A private donor provided funding to purchase glecaprevir–pibrentasvir. The funding sources had no role in the conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.",

year = "2021",

month = jan,

day = "1",

doi = "10.7326/M20-1468",

language = "English (US)",

volume = "174",

pages = "137--138",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "1",

}

TY - JOUR

T1 - Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients

T2 - An open-label nonrandomized study

AU - Durand, Christine M.

AU - Barnaba, Brittany

AU - Yu, Sile

AU - Brown, Diane M.

AU - Chattergoon, Michael A.

AU - Bair, Nichole

AU - Naqvi, Fizza F.

AU - Sulkowski, Mark

AU - Segev, Dorry L.

AU - Desai, Niraj M.

N1 - Funding Information: Financial Support: Dr. Durand is supported by National Cancer Institute grant K23CA177321-01A1. Dr. Segev is supported by grant K24DK101828 from the National Institute of Diabetes and Digestive and Kidney Diseases. A private donor provided funding to purchase glecaprevir–pibrentasvir. The funding sources had no role in the conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

PY - 2021/1/1

Y1 - 2021/1/1

UR - http://www.scopus.com/inward/record.url?scp=85097785595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097785595&partnerID=8YFLogxK

U2 - 10.7326/M20-1468

DO - 10.7326/M20-1468

M3 - Letter

C2 - 32894697

AN - SCOPUS:85097785595

SN - 0003-4819

VL - 174

SP - 137

EP - 138

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 1

ER -

Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: An open-label nonrandomized study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this